Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Feb 19, 2024 7:54am

147 Views

Post# 35887343

RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

Great news, we can start Phase I safety trials all over again... so, 6-12 months to get going. if any efficacy were to be observed, we could be in a Phase III for this combo by [add date]

Just by way of example, for the IND 213 trial that ONCY uses to underpin how effective Pela is in mBC,investors should bear in mind that that Phase II trial started in 2012.

and 12 years on it has effectively been repeated with Bracelet-1, and for which we still don't have data...

Nice idea though Noteable... great to have you back with more fortune telling stories to entice the newbies...

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"